Pfizer Inc. has paused the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy choices for women in the country. Trupti Wagh, Pfizer’s senior director of media relations for the APAC region, stated that the company is actively investigating ways to restart distribution as quickly as possible. Premarin, a treatment utilizing a blend of estrogen hormones, is primarily prescribed to alleviate vaginal dryness, painful intercourse, and other conditions linked to dropping estrogen levels during menopause.

The suspension affects a dominant market player in the segment. According to research firm Pharmarack, more than 620,000 units were sold in the 12 months ended June 2026, accounting for more than half of all sales in this treatment category. Premarin generated approximately 266 million rupees, capturing 37% of India’s conjugated estrogen market value. Sales have more than quadrupled from roughly 62 million rupees in 2022.

Market Impact and Alternatives

The discontinuation leaves patients with few treatment options, as therapies for genitourinary syndrome of menopause (GSM) remain limited in India. Sukhpreet Patel, a gynecologist and the founder of the advocacy platform MenopauseWize, highlighted the disparity between global and local availability. While international markets offer a wide range of creams, vaginal rings, and ovules, patients in India mainly rely on Premarin and Evalon, an alternative made by Torrent Pharmaceuticals. Patel noted that patient complaints regarding Premarin availability began surfacing late last year.

Demand and Demographics

The local shortage mirrors wider global constraints on hormone therapies amidst surging demand. Data from Grand View Research indicates India represented roughly 2.8% of the worldwide estrogen replacement therapy sector in 2025. The domestic market was valued at $334.5 million in 2025 and is forecasted to reach $604.6 million by 2033. The Indian Menopause Society estimates that India will have around 400 million women aged 45 and older by 2026.

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility. This approval marks the first platinum-free regimen for this patient population, supported by Phase 3 EV-304 clinical trial data presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

The approval expands upon the November 2025 FDA approval for cisplatin-ineligible patients. The EV-304 trial demonstrated that the combination significantly reduced the risk of tumor recurrence, progression, or death by 47% compared to standard neoadjuvant gemcitabine and cisplatin chemotherapy. Additionally, the regimen showed a 35% reduction in the risk of death compared to neoadjuvant chemotherapy.

Clinical Trial Results

In the EV-304 trial, patients were randomized to receive surgery with neoadjuvant and adjuvant PADCEV plus pembrolizumab or surgery with neoadjuvant chemotherapy. The treatment was administered as a planned total of 9 cycles of PADCEV and 17 cycles of pembrolizumab split before and after surgery.

The safety profile was consistent with prior experience, with Grade 3 or higher adverse events occurring in 75.7% of patients treated with the combination compared to 67.2% with chemotherapy.

Regulatory and Strategic Context

Christopher Hoimes, Director of the Bladder Cancer Program at Duke Cancer Institute and EV-304 Principal Investigator, emphasized the importance of delivering the regimen across both neoadjuvant and adjuvant phases to reduce recurrence and improve survival. Aamir Malik, Executive Vice President and Chief U.S. Commercial Officer at Pfizer, highlighted the approval as a historic turning point providing the first platinum-free combination shown to improve survival over the current standard of care.

Moitreyee Chatterjee-Kishore, Head of Oncology Development at Astellas, noted that the regimen is the first platinum-free treatment option in nearly 25 years to outperform standard chemotherapy. The collaboration between Pfizer, Astellas, and Merck focuses on evaluating the combination of PADCEV and Keytruda in patients eligible for cisplatin-based chemotherapy.